Safety, Efficacy and Pharmacokinetics of an Oral Iron Chelator Given for a Year to Pediatric Patients With Iron Overload

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE2

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-08-10

Study Completion Date

2014-05-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an open-label study to assess the pharmacokinetics, safety, efficacy and tolerability of SSP-004184AQ. The study consists of two phases: the pharmacokinetic phase, using a single 16 mg/kg dose of SSP-004184AQ; and the chronic dosing phase, during which patients will receive an additional 48 weeks of SSP-004184AQ dosing. Two age groups will be studied: 6-\<12, and 12-\<18 years old. The study is designed to initially assess the pharmacokinetics and safety of SSP-004184AQ in older children (adolescents, 12-\<18 years old) and then if deemed safe, in younger children (6-\<12 years old).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics of SSP-004184 in the Treatment of Chronic Iron Overload Requiring Chelation Therapy

NCT01604941

Iron Overload Due to Repeated Red Blood Cell Transfusions

TERMINATED PHASE2

Study for Transfusionally Iron Overloaded Children, Adolescents and Adults Using FBS0701 (SSP-004184)

NCT01671111

Iron Overload Due to Repeated Red Blood Cell Transfusions

TERMINATED PHASE2

Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere

NCT03825341

Sickle Cell Disease Thalassemia

TERMINATED PHASE2

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

NCT02274233

Iron Overload Beta-Thalassemia

TERMINATED PHASE1

Safety and Pharmacodynamic Study of an Oral Iron Chelator Given for 6 Months to Patients With Iron Overload

NCT01186419

Transfusional Iron Overload Beta-thalassemia

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Pharmacokinetic Phase: Patients will receive a single 16 mg/kg dose of SSP-004184AQ in capsule form.

Chronic Dosing Phase: Patients will receive SSP-004184AQ capsules daily for 48 weeks. Doses may range from 8-60 mg/kg/d.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Transfusional Iron Overload Beta-Thalassemia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SPD602 (26 mg/kg)

Oral SSP-004184AQ taken once daily for 48 weeks

Group Type EXPERIMENTAL

SPD602

Intervention Type DRUG

SPD602 (36 mg/kg)

Oral SSP-004184AQ taken once daily for 48 weeks. Starting dose based on transfusion burden and iron overload status. Doses may range from 8-60mg/kg/day depending on clinical response.

Group Type EXPERIMENTAL

SPD602

Intervention Type DRUG

SPD602 (16 mg/kg)

A single dose given in the initial pharmacokinetic phase.

Group Type EXPERIMENTAL

SPD602

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SPD602

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

SSP-004184, deferitazole

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Parents willing and able to sign the approved informed consent for their children and subjects between the ages of 6 and \<18 years willing and able to provide their assent (based on institutional guidelines).
* Able to swallow whole capsules.
* Age \>6 and \<18 years.
* Transfusion-dependent subjects who have transfusional iron overload requiring chronic treatment with deferoxamine, deferasirox, or deferiprone. A transfusion dependent subject is defined in this study as one with a minimum transfusion history totaling more than 20 units of packed red blood cells OR a calculated iron load based on transfusion history of 200mg/kg AND a transfusion requirement of 7 or more transfusions per year; or, in subjects with sickle cell anemia, be iron overloaded but can be receiving transfusion exchange therapy in lieu of transfusions.
* In the opinion of the Investigator (and in consultation with the subject's parents), the subject is able to discontinue all existing iron chelation therapies for a minimum period of 1-5 days prior first dose of SSP-004184AQ, for the initial pharmacokinetic period of 8 days (if applicable), and for up to 49 weeks if continuing into the chronic dosing phase.
* Subjects able to have an MRI must have:

1. liver iron concentration \>2 and \<30mg/g (dry weight, liver) by FerriScan® R2
2. cardiac MRI T2\* \>10ms (Note: Subjects not able to have an MRI will be considered iron overloaded on the basis of serum ferritin only.)
* Serum ferritin \>500ng/mL at Screening.
* Mean of the previous 3 pre-transfusion hemoglobin concentrations greater than or equal to 7.5g/dL.
* If appropriate, depending on age, female subjects of child-bearing potential need to use a medically acceptable method for birth control from screening until 30 days after the last dose of the study drug. Females of child-bearing potential must have a negative serum beta-HCG pregnancy test at the Screening Visit and a negative urine pregnancy test at the Baseline Visit. Females of child-bearing potential must agree to abstain from sexual activity that could result in pregnancy or agree to use acceptable methods of contraception.

Exclusion Criteria

* As a result of medical review, physical examination (including height and weight) or Screening investigations, the Principal Investigator considers the subject unfit for the study.
* Iron overload from causes other than transfusional hemosiderosis.
* Severe cardiac dysfunction.
* Non-elective hospitalization within the 30 days prior to Baseline testing.
* Evidence of clinically significant oral, cardiovascular, gastrointestinal, hepatic, biliary, renal, endocrine, pulmonary, neurologic, psychiatric, or skin disorder that contra-indicates dosing with SSP-004184AQ.
* Evidence of significant renal insufficiency, eg, serum creatinine above the upper limit of normal or proteinuria greater than 1 gm per day.
* Known sensitivity to any ingredient in the SSP-004184AQ formulation.
* Platelet count below 100,000/µL or absolute neutrophil count less than 1500/mm3 at Screening.
* ALT \>180 IU/L at Screening.
* Use of any investigational agent within the 30 days prior to Baseline testing.
* Pregnant or lactating females.
* Cardiac left ventricular ejection fraction a) Below the locally determined normal range in the 12 months prior to screening by echocardiography or MRI or \<50% at Baseline testing by MRI (echocardiograph is acceptable for LVEF if MRI information is not available).

Minimum Eligible Age

6 Years

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No